MedCity News
OCTOBER 29, 2024
Large language models will soon become a much bigger part of doctors’ clinical workflows, former FDA Commissioner Scott Gottlieb said Tuesday at the 3rd Annual Summit on the Future of Rural Health Care. The post ‘You Almost Have to Be Doing It’: Why Scott Gottlieb Thinks All Doctors Will Use LLMs Soon appeared first on MedCity News.
Fierce Pharma
NOVEMBER 1, 2024
With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing up to pursue yet another indication for its star GLP-1 medicine semagluti | Novo Nordisk on Friday revealed that its star GLP-1 semaglutide met the mark in a late-stage MASH study. The positive results build on the thesis that GLP-1s could become a foundational piece in the treatment paradigm for the fatty liver disease, according to analysts at William Blair.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Commerce
OCTOBER 31, 2024
With today's pharmacy landscape shaken by unprecedented and wider disruption to healthcare support and delivery, community and independent entities strive to remain an integral cog in the mix.
PharmaVoice
OCTOBER 28, 2024
As antimicrobial resistance rises, researchers are running out of time to fight each new wave of superbugs. And the funding isn’t enough.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
MedCity News
OCTOBER 28, 2024
The healthcare industry’s inability to coordinate care effectively and at scale is the single biggest issue in the sector, said Tampa General Hospital CEO John Couris. The post This Problem Keeps Hospital Execs Up at Night, Tampa General Hospital CEO Says appeared first on MedCity News.
Fierce Pharma
OCTOBER 28, 2024
Novartis and Apellis Pharmaceuticals have rolled out detailed data on iptacopan and pegcetacoplan, respectively, as they race for the prize in a type of rare kidney disease. | Novartis and Apellis dropped new data on their respective meds, iptacopan and pegcetacoplan, in the rare kidney disease C3 glomerulopathy. While Apellis' drug seems to have an efficacy edge based on a cross-trial comparison, Novartis may have gotten the jump by filing for approvals ahead of its competitor.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Referral MD
NOVEMBER 1, 2024
MT. PLEASANT, S.C. , Nov. 1, 2024 /PRNewswire-PRWeb/ — ReferralMD, a leader in healthcare technology solutions, announced today that it was recognized as a 2024 Top Company in Conversational AI upon the conclusion of extensive research and company outreach by AVIA Marketplace, the leading digital health marketplace. ReferralMD offers a comprehensive platform that seamlessly integrates with Electronic Health Records (EHR), Practice Management, and Scheduling systems, automating time-consu
MedCity News
OCTOBER 30, 2024
After the FDA delayed the approval of MDMA-assisted therapy for PTSD, there’s still a way forward for psychedelic medicines, experts said at HLTH. The post What’s Next for Psychedelic Medicines? appeared first on MedCity News.
Fierce Pharma
OCTOBER 31, 2024
Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | The FDA this week revised its shortage list to note that the.25 mg starter dose of Novo’s semaglutide-based obesity med Wegovy is now available in the U.S.
PharmaVoice
NOVEMBER 1, 2024
Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the outlook for patients feels shakier. But there’s still hope in the pipeline.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
OCTOBER 30, 2024
Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions for drugs in its class.Simply shifting one vial of the anti-amyloid antibody from the first infusion to the third infusion of the titration phase of dosing – the period used to achieve therapeutic levels in the body – is enough to lower the incidence of a potentially serious side effect known as ARIA-E, accordi
MedCity News
NOVEMBER 1, 2024
GoodRx announced a new e-commerce solution starting with over-the-counter birth control pill Opill. It also is offering new affordability programs for menopause medications with Pfizer. The post GoodRx Expands Women’s Health Options with New Birth Control and Menopause Offerings appeared first on MedCity News.
Fierce Pharma
OCTOBER 31, 2024
Bristol Myers’ $1.5 billion restructuring initiative that runs through 2025 may not be the end of the company’s ongoing efficiency push. | Bristol Myers' $1.5 billion restructuring initiative that runs through 2025 may not be the end of the company's ongoing efficiency push. The drugmaker is "exploring opportunities to further improve productivity and efficiency," CEO Chris Boerner said Thursday.
Impetus Digital
OCTOBER 29, 2024
Pharma-exclusive Webinar: Next-gen Virtual Tools for Education & Learning in the Life Sciences About the webinar Join us for one of three webinar sessions, tailored exclusively for Pharma leaders. Between November 18–20, we will delve into the future of educational tools in the life sciences industry. Our expert speakers will unveil the latest virtual tools that are reshaping how professionals engage with and educate HCPs, patients, and internal teams.
pharmaphorum
NOVEMBER 1, 2024
FDA advisors vote against Lexicon Pharma's type 1 diabetes and chronic kidney disease therapy sotagliflozin ahead of December verdict
MedCity News
OCTOBER 31, 2024
For those who rely on these treatments, affordable medication access is a matter of health, freedom, and dignity, and their mechanisms and outcomes are non-partisan. The post Financial Security, Lasting Relief: How the Inflation Reduction Act Restores Health to Patients and Hope to Their Doctors appeared first on MedCity News.
Fierce Pharma
NOVEMBER 1, 2024
An FDA announcement last year of an investigation into the risk of patients developing secondary cancers following the treatment of CAR-T cell therapies sent shock waves across the industry. | An FDA investigation last year into the risk of patients developing secondary cancers following the treatment of CAR-T cell therapies sent shock waves across the industry.
European Pharmaceutical Review
OCTOBER 30, 2024
A paper has a described the first reported use of nanoemulsions as a novel delivery vehicle for the oral drug bedaquline (BDQ) “with high loading efficiency as a liquid dosage form”, according to the authors. The researchers explained that in recent decades, the industry has placed significant focus on lipid-based nanocarrier formulations for oral drug delivery.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
OCTOBER 31, 2024
The European Commission has delivered a hefty fine to Teva for abusing a dominant position in multiple sclerosis by artificially extending the patent protection for former blockbuster Copaxone.
MedCity News
OCTOBER 28, 2024
Novartis is getting global rights to a Monte Rosa Therapeutic molecular glue degrader drug in early clinical testing as a potential treatment for autoimmune disorders. The deal comes months after the pharma giant landed rights to an Arvinas targeted protein degrader for cancer. The post Novartis to Pay $150M for Monte Rosa Glue Drug in the Clinic for Immunology Indications appeared first on MedCity News.
Fierce Pharma
OCTOBER 30, 2024
Sales of Eli Lilly’s diabetes and weight loss drugs fell far short of expectations in the third quarter, leading the juggernaut company to reduce its annual revenue guidance and triggering speculat | Sales of Eli Lilly’s diabetes and weight loss drugs fell far short of analyst expectations in the third quarter, leading the juggernaut company to reduce its annual revenue guidance and triggering speculation that skyrocketing demand for the blood sugar modulating treatments has maxed out.
PharmaVoice
OCTOBER 30, 2024
Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug market.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
pharmaphorum
OCTOBER 30, 2024
Novartis says FDA approval for frontline use of its leukaemia drug Scemblix will boost the number of eligible patients four-fold, as it hunts blockbuster sales
MedCity News
OCTOBER 31, 2024
In this month’s episode, Senior Reporter Katie Adams discussed some of the executive moves, exits and layoffs that recently occurred in the healthcare world. She also interviewed Amy Abernethy, who recently co-founded Highlander Health with fellow healthcare veteran Brad Hirsch. The post MedCity Moves Podcast: Recent Hires, Layoffs & an Interview with Amy Abernethy, Co-Founder of Highlander Health appeared first on MedCity News.
Fierce Pharma
OCTOBER 31, 2024
With U.S. | With U.S. sales of $392 million in the third quarter, Regeneron’s high-dose version of Eylea is closing in on blockbuster sales in its first full year on the market. The bad news for the company, however, is that while sales from Eylea HD increased by 29% sequentially, this didn't translate to a similar bump in overall U.S. revenue for the Eylea family of eye medications.
Pharmaceutical Commerce
NOVEMBER 1, 2024
Analysis finds that while basic Part D coverage costs have decreased by 4%, mid- and high-tier plans have seen hikes of 4% and 21%, respectively.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
pharmaphorum
OCTOBER 28, 2024
Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class therapies for the disorder.Data reported at the Kidney Week 2024 congress in San Diego showed that felzartamab was able to achieve "substantial" reductions in proteinuria and stabilised kidney function in the 54-subject IGNAZ study that extended for 18 months after the last dose of the antibody.
MedCity News
OCTOBER 30, 2024
The status quo is simply untenable for many companies as health insurance costs spiral. From family-owned businesses to large enterprises, employers are taking advantage of an alternative designed by politicians on both sides of the aisle. The post How a Bipartisan Program Can Help You Avoid Costly Health Insurance Renewals appeared first on MedCity News.
Fierce Pharma
OCTOBER 29, 2024
Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an accelerated approval to treat newly diagnosed patients. | Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an accelerated approval to treat newly diagnosed patients.
PharmaVoice
OCTOBER 31, 2024
Pfizer, J&J, Biogen and Novartis are banking on new products to make up for maturing blockbusters, but future growth is not guaranteed.
Expert insights. Personalized for you.
124 
Let's personalize your content